Elastomeric Infusion Pumps Market Report 2022: Rising Preference for Long-Term Home Healthcare Drives Growth

The “Elastomeric Infusion Pumps Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030″ report has been added to ResearchAndMarkets.com’s offering.

Elastomeric Infusion Pumps Market is Expected to Grow at 7.0% from 2022-2030.

Elastomeric infusion pumps are disposable medical used for the administration of liquid drugs such as analgesics, antibiotics, chemotherapy medications, etc.

The rise in the adoption of elastomeric pumps is attributed to driving factors such as growth in demand for disposable ambulatory pumps, rising preference for long-term home healthcare, growing hospitalization rates, and evolving reimbursement policies.

Variable Rate Infusion Pumps are expected to show the fastest growth

For the purpose of this study, the global elastomeric infusion pumps market is studied for various segments based on product types, treatment types, usage areas, and geographical distribution. The continuous rate pumps held the largest market, while the variable rate infusion pumps are expected to bolster the fastest growth during the forecast period due to product innovation. In terms of treatment type, the pain management segment held the largest market due to the increasing usage of elastomeric infusion pumps for port operative pain management.

Elastomeric infusion pumps have applications for pain management, infection management, cytostatic treatment, chelation therapy. Major application of infusion pump is for postoperative analgesia for pain management. Thus, pain management occupies the largest share of in application segment of elastomeric infusion market. It is followed by cytostatic treatment since infusion pump therapy proves more effective and well-tolerated in patient.

Ambulatory Care Segment is Expected to Exhibit Exponential Growth

The ambulatory care segment is expected to exhibit exponential growth in the usage area segment, while hospitals held the largest share in the elastomeric infusion pumps market due to better reimbursement scenarios and cost structure. In terms of geography, North America dominated the global elastomeric infusion pumps market due to greater acceptance of elastomeric infusion pumps, developed healthcare infrastructure, and well organized reimbursement scenarios. Asia Pacific is expected to grow at the fastest rate during the forecast period to increasing investment and market entry of manufacturers in the region.

Among the considered usage areas, hospitals and clinics currently dominate the global elastomeric infusion pumps market. Higher affordability, greater awareness in hospital staff, and potential of elastomeric infusion pump in reducing manpower and treatment costs in the long run greatly contribute to the dominance of hospitals and clinics in the market. Furthermore, better reimbursement policies and growing preference for home care in order to save treatment costs have led to rapid market growth of home care segment during the forecast period.

Asia Pacific Dominates the Market

In the base 2020, North America was observed as the largest market for elastomeric infusion pumps followed by Europe. In North America and Europe there is an increase in the chronic diseases like gastrointestinal complications, abdominal hernia’s, etc. Asia-Pacific and Middle East and Africa are potential market due to the high prevalence of chronic diseases requiring surgical procedure but less disease awareness.

Prominent Key Players

  • Baxter International, Inc.
  • B. Braun Melsungen
  • PFM Medical
  • Gamastech SRL
  • Halyard Health, Inc.
  • Nipro Corporation
  • Woo Young Medical Co.


Market Segmentation
Type

  • Continuous Rate Pumps
  • Variable rate pumps

Treatment

  • Pain Management(Anesthetics and Analgesics)
  • Infection Management (Antibiotics/antivirals)
  • Cytostatic Treatment
  • Others (Chelation, etc)

Usage Area

  • Hospitals and Clinics
  • Ambulatory Care
  • Home Care

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Elastomeric Infusion Pumps market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Elastomeric Infusion Pumps market?
  • Which is the largest regional market for Elastomeric Infusion Pumps market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Elastomeric Infusion Pumps market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Elastomeric Infusion Pumps market worldwide?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Elastomeric Infusion Pumps Market: Competitive Analysis

4. Elastomeric Infusion Pumps Market: Macro Analysis & Market Dynamics

5. Elastomeric Infusion Pumps Market: By Type, 2020-2030, USD (Million)

6. Elastomeric Infusion Pumps Market: By Treatment, 2020-2030, USD (Million)

7. Elastomeric Infusion Pumps Market: By Usage Area, 2020-2030, USD (Million)

8. North America Elastomeric Infusion Pumps Market, 2020-2030, USD (Million)

9. UK and European Union Elastomeric Infusion Pumps Market, 2020-2030, USD (Million)

10. Asia Pacific Elastomeric Infusion Pumps Market, 2020-2030, USD (Million)

11. Latin America Elastomeric Infusion Pumps Market, 2020-2030, USD (Million)

12. Middle East and Africa Elastomeric Infusion Pumps Market, 2020-2030, USD (Million)

13. Company Profile

Companies Mentioned

  • Baxter International Inc.
  • B. Braun Melsungen
  • PFM Medical
  • Gamastech SRL
  • Halyard Health Inc.
  • Nipro Corporation
  • Woo Young Medical Co.

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”